对登革热出血热的潜在药物的鉴定:基于网络的药物再定位研究
Praveenkumar Kochuthakidiyel Suresh1, Gnanasoundari Sekar2, Kavya Mallady3
1Central Research Facility, Sri Ramachandra Institute of Higher Education and Research, Chennai, India.
JMIR bioinformatics and biotechnology
|June 27, 2024
概括
药物重新定位确定了45种严重登革热 (DHF) 的潜在治疗方法. 阿司匹林,卡普托普里尔和里洛纳塞普特看起来很有前途,但需要进行临床试验来确认安全性和有效性.
科学领域:
- 病毒学 病毒学
- 药理学 药理学是指药理学的学科.
- 计算生物学 计算生物学
背景情况:
- 登革热可以发展为严重的登革热出血热 (DHF),这是一个潜在的致命状况,目前没有抗病毒治疗.
- 药物再利用提供了一个快速的策略,通过调查现有的FDA批准的药物来开发DHF疗法.
- 网络药理学在识别病毒性疾病的潜在候选药物方面发挥了重要作用.
研究的目的:
- 确定FDA批准的药物,可以用于治疗登革热出血性发烧 (DHF).
- 探索针对病毒感染,发烧症状和DHF的现有药物作为药物重新用途的潜在候选者.
- 为了利用网络药理学来选药物对人类-DHF病毒相互作用.
主要方法:
- 利用GeneCards和DrugBank数据库识别人类-DHF病毒交互基因及其药物标.
- 进行基于网络的分析,以确定枢纽基因和潜在的可重用药物.
- 进行了功能丰富和网络分析,以探索路径,蛋白质-蛋白质相互作用,基因表达组织和疾病关联.
主要成果:
- 通过对病毒与宿主相互作用和治疗点的分析,确定了45种潜在的可重用药物.
- 网络分析表明阿司匹林,卡普托普里尔和里洛纳塞普特是治疗高血压炎的有希望的候选药物.
- 基因丰富分析揭示了与免疫系统途径和内皮细胞的显著关联,突出了潜在的抗凝剂作用. 鉴定了糖尿病和癌症的DHF患者的致病性风险增加.
结论:
- 虽然阿司匹林在登革热中带有出血风险,但低剂量使用可能有利于与血栓形成相关的DHF.
- 药物重新定位需要严格的临床验证和剂量优化,才能得到广泛的处方.
- 进一步的国际试验至关重要,以了解DHF的病原性,并验证重用药物的疗效.
相关概念视频
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...


